PRIA Logo™
Take the PRIA Score
HR685119th CongressWALLET

SAVE Moms and Babies Act of 2025

Sponsored By: Representative Latta

Introduced

Summary

Ban on new approvals and strict federal controls for abortion drugs. This bill would prohibit FDA approval of new abortion drugs and bar new investigational uses under the Federal Food, Drug, and Cosmetic Act (FDCA). It would also require existing abortion drugs to comply with a minimum risk evaluation and mitigation strategy and impose tight reporting and in-person dispensing rules.

Show full summary
  • Pregnant people and families: Limits how and when approved abortion drugs can be used by barring label changes to allow use after 70 days gestation and requiring in‑person administration by the prescribing clinician.
  • Health care practitioners: Forces prescribers to be certified, to be able to date pregnancies and diagnose ectopic pregnancies, to provide or arrange surgical care for incomplete abortion or severe bleeding, and to ensure access to transfusion and resuscitation facilities.
  • Manufacturers and regulators: Stops new approvals and rescinds investigational use exemptions after three years for prohibited studies. It also mandates a risk evaluation and mitigation strategy (REMS) with manufacturer and prescriber reporting of deaths and adverse events and package serial number tracking.

Your PRIA Score

Score Hidden

Personalized for You

How does this bill affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Bill Overview

Analyzed Economic Effects

3 provisions identified: 0 benefits, 2 costs, 1 mixed.

No new FDA approvals for abortion drugs

If enacted, FDA would be barred from approving new abortion drugs. FDA would also be barred from allowing clinical trials for such drugs or any study that knowingly destroys an unborn child. Some pre‑existing research exemptions would end 3 years after enactment if they would then be disallowed. This could reduce future access and keep new medication options off the market.

Stricter in-person rules for abortion drugs

If enacted, current abortion drugs could not be labeled for use after 70 days of pregnancy. The drug would have to be given in person by the prescriber in a clinic, office, or hospital; pharmacy dispensing would be barred. A strict safety plan (REMS) would require prescriber certification, dating the pregnancy, checking for ectopic pregnancy, handling complications, and ensuring access to transfusion and resuscitation. Prescribers could not act as pharmacists. Doctors, manufacturers, and other health care practitioners would have to report deaths and other adverse events to FDA; patients must get written risk info and sign an acknowledgment. Use would be reported as state law requires, or like a surgical abortion where no state rule exists. These steps could improve monitoring and informed consent but would limit remote access and may raise travel and care costs.

Defines abortion drugs and allows more state rules

If enacted, the bill would define key terms like “abortion drug,” “adverse event,” “gestation” (counted from the first day of the last period), “health care practitioner,” and “unborn child.” These definitions decide which drugs, events, and providers must follow the new limits and reports. The bill would also not stop federal or state governments from adding more rules on these drugs. That could lead to stricter requirements in some places.

Free Policy Watch

You just read the policy. Now see what it costs you.

Pick a topic. PRIA runs your household against live legislation and sends you a free personalized readout.

Pick a topic to get started

My TaxesMy HealthMy BudgetMy MoneyMy Freedom
Or tell us something more specific

Sponsors & CoSponsors

Sponsor

Latta

OH • R

Cosponsors

  • Rouzer

    NC • R

    Sponsored 1/23/2025

  • Brecheen

    OK • R

    Sponsored 1/23/2025

  • Strong

    AL • R

    Sponsored 1/23/2025

  • Miller (IL)

    IL • R

    Sponsored 1/23/2025

  • Webster (FL)

    FL • R

    Sponsored 1/23/2025

  • Finstad

    MN • R

    Sponsored 1/23/2025

  • Aderholt

    AL • R

    Sponsored 1/23/2025

  • Feenstra

    IA • R

    Sponsored 1/23/2025

  • Smith (NJ)

    NJ • R

    Sponsored 1/23/2025

  • Fulcher

    ID • R

    Sponsored 1/23/2025

  • Rep. Flood, Mike [R-NE-1]

    NE • R

    Sponsored 1/23/2025

  • Mann

    KS • R

    Sponsored 1/23/2025

  • Rep. Harris, Andy [R-MD-1]

    MD • R

    Sponsored 1/23/2025

  • Fong

    CA • R

    Sponsored 1/23/2025

  • Ellzey

    TX • R

    Sponsored 1/23/2025

  • Rep. Weber, Randy K. Sr. [R-TX-14]

    TX • R

    Sponsored 1/23/2025

  • Rep. McCormick, Richard [R-GA-7]

    GA • R

    Sponsored 1/23/2025

  • Rep. Moolenaar, John R. [R-MI-2]

    MI • R

    Sponsored 1/23/2025

  • Rep. Ogles, Andrew [R-TN-5]

    TN • R

    Sponsored 1/23/2025

  • Guest

    MS • R

    Sponsored 1/23/2025

  • Rep. Higgins, Clay [R-LA-3]

    LA • R

    Sponsored 1/23/2025

  • Rep. Palmer, Gary J. [R-AL-6]

    AL • R

    Sponsored 1/23/2025

  • Moore (NC)

    NC • R

    Sponsored 1/23/2025

  • Rep. Shreve, Jefferson [R-IN-6]

    IN • R

    Sponsored 1/23/2025

  • LaHood

    IL • R

    Sponsored 1/23/2025

  • Fitzgerald

    WI • R

    Sponsored 2/11/2025

  • Biggs (SC)

    SC • R

    Sponsored 2/11/2025

  • Rep. Moore, Barry [R-AL-1]

    AL • R

    Sponsored 9/19/2025

  • Bost

    IL • R

    Sponsored 10/31/2025

  • Fedorchak

    ND • R

    Sponsored 4/14/2026

  • Thompson (PA)

    PA • R

    Sponsored 4/14/2026

  • Cloud

    TX • R

    Sponsored 4/14/2026

  • Hageman

    WY • R

    Sponsored 4/14/2026

  • Stutzman

    IN • R

    Sponsored 4/14/2026

  • Rogers (AL)

    AL • R

    Sponsored 4/14/2026

  • Kelly (PA)

    PA • R

    Sponsored 4/14/2026

  • Rep. Harrigan, Pat [R-NC-10]

    NC • R

    Sponsored 4/16/2026

  • Houchin

    IN • R

    Sponsored 4/16/2026

  • Norman

    SC • R

    Sponsored 4/16/2026

  • Rep. Smith, Adrian [R-NE-3]

    NE • R

    Sponsored 4/20/2026

  • Messmer

    IN • R

    Sponsored 4/21/2026

  • Kennedy (UT)

    UT • R

    Sponsored 4/16/2026

  • Rep. Cline, Ben [R-VA-6]

    VA • R

    Sponsored 4/20/2026

  • Hern (OK)

    OK • R

    Sponsored 4/15/2026

  • Bean (FL)

    FL • R

    Sponsored 4/21/2026

  • Timmons

    SC • R

    Sponsored 4/16/2026

  • Rep. Clyde, Andrew S. [R-GA-9]

    GA • R

    Sponsored 4/21/2026

  • Rep. Steube, W. Gregory [R-FL-17]

    FL • R

    Sponsored 4/21/2026

  • Rep. Cammack, Kat [R-FL-3]

    FL • R

    Sponsored 4/21/2026

  • Onder

    MO • R

    Sponsored 4/22/2026

  • McGuire

    VA • R

    Sponsored 4/27/2026

  • Rep. Hill, J. French [R-AR-2]

    AR • R

    Sponsored 4/28/2026

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation

Take It Personal

Get Your Personalized Policy View

Take the PRIA Score to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.

Already have an account? Sign in